Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XBJHU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LY-3076226
|
|||||
| Synonyms |
Anti-FGFR3 Ab IMC-D11; LY 3076226; LY-3076226; LY3076 226; LY3076226
Click to Show/Hide
|
|||||
| Organization |
Eli Lilly & Co.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Structure |
|
|||||
| Antibody Name |
IMC-D11
|
Antibody Info | ||||
| Antigen Name |
Fibroblast growth factor receptor 3 (FGFR3)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
ravtansine
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
